Elias Jabbour

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Elias Jabbour
Jun 27, 2025, 18:17 | Insight
MD Anderson Research Highlights
MD Anderson Research Highlights for June 26, 2025 Promising treatment results for blood cancers, colorectal…
Jun 20, 2025, 10:48 | Opinion
Aaron Goodman: HMA-Venetoclax-Ivosidenib in Frontline AML
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared…
Jun 12, 2025, 23:01 | Insight
Nitin Jain: Happy to share results of investigator initiated trial of Ruxolitinib in Ph-Like ALL
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared…
May 15, 2025, 13:36 | Science
Hagop Kantarjian: Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
Hagop Kantarjian, Associate Vice President for Global Academic Programs at MD Anderson Cancer Center, shared…
May 9, 2025, 12:49 | Science
The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia
ACS Journal Cancer shared a post on X: "This new review article led by Hagop…
Mar 25, 2025, 15:36 | Blog
Naveen Pemmaraju: Discussing our collaborative Leukemia-CT Surgery manuscript with Mara Antonoff
Naveen Pemmaraju, Professor and Director of the BPDCN Program at the Department of Leukemia at…
Mar 19, 2025, 12:12 | Blog
Hagop Kantarjian: Expert recommendations on using MRD in ALL
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Mar 11, 2025, 08:03 | Drugs
Naveen Pemmaraju: Bromodomain and PLX51107 with Azacitidine in Patients with R/R Myeloid Malignancies
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University…
Feb 27, 2025, 11:09 | Science
Nitin Jain: Treatment-free remission in Ph+ ALL
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared…
Feb 26, 2025, 16:33 | Science
Hagop Kantarjian: Treatment-free remission in non-transplanted Ph+ ALL patients
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Jan 8, 2025, 15:17 | Insight
SOHO has launched SOHO Insider: A New Resource for the Latest in Hematologic Oncology
The Society of Hematologic Oncology (SOHO) has officially launched SOHO Insider, a comprehensive new publication…
Dec 26, 2024, 14:37 | Insight
Jayastu Senapati: Largest reported cohort in secondary AML
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “Check…
Dec 11, 2024, 14:53 | Insight
Five articles suggested by Yan Leyfman
Yan Leyfman MD is the Co-founder and executive director of MedNews Week. He is also the…
Dec 5, 2024, 16:20 | Insight
ASH24 studies from MD Anderson presented by Jayastu Senapati
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “ASH24…
Dec 5, 2024, 16:16 | Insight
Nitin Jain: Relapsed T-ALL remains a very challenging unmet need
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared…
Dec 2, 2024, 19:24 | Insight
Naveen Pemmaraju: PVO combination program for frontline CLL treatment
Naveen Pemmaraju shared a post on X: '' ASH Kudos to Dr. Nitin Jain for an…
Dec 1, 2024, 08:51 | Blog
Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?
KhalisMustafayev, Research Scientist at Miami Cancer Institute, shared on X: "Are BCR::ABL1 TKIs safe for…
Nov 30, 2024, 15:27 | Insight
Obe-cel CAR T Therapy Achieves High Response Rates in R/R B-cell ALL: FELIX Trial Results
Trial results supported recent FDA approval for patients with relapsed/refractory disease Patients with relapsed or…
Nov 16, 2024, 20:28 | Insight
Naveen Pemmaraju: Our new report on DDX for mediastinal mass in patient with B-ALL
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the…
Oct 1, 2024, 11:05 | Blog,Insight
Mohamed Benlazar: General approach to patients with AML
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…
Aug 10, 2024, 12:57 | Insight
MD Anderson Research Highlights
Featuring cell biology insights, new targets to prevent dysphagia, improved treatments for advanced cancers and…
Aug 10, 2024, 12:55 | Insight
Jayastu Senapati: Utlility of baseline liver elastography in adults with B cell-ALL with liver toxicity
Jayastu Senapati shared a post on X: "Check out our paper just published in Blood…
Aug 8, 2024, 10:24 | Blog
Talha Badar: Advance line of TKI vs allogenic stem cell transplantation in resistant CML
Talha Badar shared a post on X: ''Treatment of resistant chronic myeloid leukemia (CML); advanced…
Jul 23, 2024, 22:30 | Blog
Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective
Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…
Jul 23, 2024, 06:05 | Blog
Talha Badar: The role of allogeneic stem cell transplantation in Ph+ve ALL
Talha Badar shared on X: "The role of allogeneic stem cell transplantation in Ph+ve ALL? Outcome…
Jul 20, 2024, 14:27 | Insight
Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…
Jul 19, 2024, 13:27 | Insight
Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…
Jun 21, 2024, 09:47 | Blog
Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL - ALL Hub
ALL Hub shared a post on X: "CONGRESS | POSTER | EHA2024 | Elias Jabbour…
Jun 2, 2024, 22:16 | Insight
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Clinical trial results suggest new treatment options could reduce need for stem cell transplants and…
May 19, 2024, 10:00 | Blog
Hagop Kantarjian: A comprehensive review of ponatinib in CML and Ph+ ALL
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: "A comprehensive…
Feb 18, 2024, 15:51 | Blog
Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…
Nov 6, 2023, 03:36 | Drugs
Hagop Kantarjian: Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%
Hagop Kantarjian, Chair of MD Anderson Cancer Center, shared a post on Twitter: Inotuzumab is…
All: 32 Posts: 1 - 100
Special Coverage